Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil (

C. A. Goncalves, MD, Head of the S100B lab
B. S. Fernandes, MD (currently visiting scientist at Deakin University, Geelong, Australia)
Original research and meta-analyses on S100B, neuro- / gliotrophic factors, neuroinflammation and energy metabolism in schizophrenia and affective disorders are a main focus of our collaboration since 2012.


Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil (

D. Martins-de-Souza, PhD, Head of the neuroproteomics laboratory

Joined mass spectrometry proteomic studies on human blood, cerebrospinal fluid and brain tissue from patients with schizophrenia, affective disorders, and matched controls are a focus of our research activities aiming to the development of diagnostic and prognostic biomarkers in psychiatry.


Department of Clinical Immunology & Rheumatology, Medical School Hanover, Germany (

R. Jacobs, PhD, Head of the innate immunology / NK cell laboratory

Flow cytometric and cell culture studies on the role of B-, T-lymphocytes and NK-cells with particular focus on S100B expressing lymphocyte subsets are the main focus of our collaboration (in the context of the neuroinflammatory hypothesis of schizophrenia).


Department of Neurology, University of Magdeburg, Germany (

M. Matzke, MD, Head of the Multiple Sclerosis Outpatient Department

Magdeburg´s University Department of Neurology is cooperating with our laboratory in order to develop a serum test for of Multiple Sclerosis and to explore the significance of antineuronal autoantibodies in neuropsychiatric disorders.


Department of Psychiatry, University of Magdeburg, Germany (

Bernhard Bogerts, MD, Chair

Hans-Gert Bernstein, PhD

Stefan Busse, MD - Mandy Busse, PhD

Kolja Schiltz, MD (

Martin Walter, MD (

Our workgroup is closely collaborating with B. Bogerts and H-G. Bernstein in several postmortem-studies regarding the pathophysiology of schizoaffective disorders.

Immune changes related to normal aging and different types of dementa are analyzed in close collaboration with S. Busse and M. Busse.
Currently, in collaboration with K. Schiltz we are joining biomarker serum analyses with a multimodal imaging approach in order to identify the contribution of different metabolic abnormalities that have been identified in schizophrenia.

In collaboration with M. Walter we apply MRI spectroscopy of Glutamate and GABA as well as advanced resting state fMRI analyses and high-field MRI (7T) in patients with affective disorders.


Institute of Biochemistry and Cell Biology, University of Magdeburg, Germany (

G. Keilhoff, PhD, Head of the Laboratory of Medical Neurobiology

Immunofluorescent analyses of human brain tissue, as well as glial and neuronal cell culture studies on the influence of metabolic stress and neuropharmacologic drugs on the expression of neurotrophic proteins and are the main focus of our well-established collaboration (since 2006).

Institute of Biotechnology, Centre for Neuropsychiatric Research, University of Cambridge, UK (

S. Bahn, MD, PhD; MRCPsych, Project Leader

We are collaborating with the Bahn Laboratory since 2007 concerning mass spectrometry-, microarray- and MULTIPLEX-ELISA-biomarker diagnostics in neuropsychiatric disorders. Schizophrenia-related disturbances in glucose metabolism are another main focus of our research projects.


Institute of Clinical Chemistry & Pathobiochemistry, University of Magdeburg, Germany (

B. Isermann, MD, Chair, S. Westphal, MD, Outpatient Department of Metabolic Medicine

Our cooperation is aiming to unravel endocrinologic changes in schizophrenia and affective disorders with particular focus on insulin, glucose and lipid metabolism and the role of stress-axis activation in major psychiatric disorders.


Institute of Experimental Immunology, EUROIMMUN, Lübeck, Germany (

W. Stöcker, MD, Director

Blood samples from our scientific blood bank are analyzed by indirect immunofluorescence (BIOCHIP-Technology) for the presence of antineuronal antibodies and autoimmune endocrine disorders. 


Institute of Forensic Medicine, Medical University of Gdańsk, Poland (

T. Gos, MD, Stereology and histopathological research in schizophrenia and affective disorders are the main focus of our research projects with T. Gos, MD. He has continous close contacts to our Department as a visiting scientist in order to strengthen our German-Polish collaboration in postmortem-research.


Institute of Neuropatholgy, University of Magdeburg, Germany (

C. Mawrin, MD, Chair

Sterologic postmortem-studies as well as biochemical studies on frozen tissue from our joined BrainNet center (Institute of Neuropathology and Department of Psychiatry) are focusing on neuroinflammatory and neurodegenerative changes in schizophrenia and affective disorders.


Max Planck Institute of Experimental Medicine, Göttingen, Germany (

H. Ehrenreich, MD, DVM, Head of clinical neurosciences

The pathophysiological significance of antineuronal neurotransmitter receptor autoantibodies in schizophrenia, affective disorders, and different types of dementia is explored in collaboration with H. Ehrenreich since 2013.


Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (

M. L. Schroeter, MD, PhD, Head of the cognitive neuropsychiatry research group
Joined original research as well as meta-analyses on S100B and biomarkers of glial pathology in schizophrenia and affective disorders are a strong focus of our collaboration with M. Schroeter since 2009.


Psychiatric Clinic of the Ludwig-Maximilians-University, Munich, Germany (

P. Falkai, MD,Chair
A. Schmitt, MD, Head of the neurobiology in schizophrenia research group
Schizophrenia-related original histopathological research on post-mortem brain tissue from the Magdeburg / Düsseldorf brain bank are a main focus of our research.